Another study has highlighted the potential of MCAM-targeted radioimmunotherapy in malignant mesothelioma by using CD146-targeting antibody OI-3 coupled with 212Pb (212Pb-TCMC-OI-3) [106]. The gene discussed is COL1A1; the disease is malignant mesothelioma.